GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (NAS:KPTI) » Definitions » E10

Karyopharm Therapeutics (Karyopharm Therapeutics) E10 : $-3.09 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Karyopharm Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Karyopharm Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.360. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-3.09 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-04-29), Karyopharm Therapeutics's current stock price is $1.1103. Karyopharm Therapeutics's E10 for the quarter that ended in Dec. 2023 was $-3.09. Karyopharm Therapeutics's Shiller PE Ratio of today is .


Karyopharm Therapeutics E10 Historical Data

The historical data trend for Karyopharm Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karyopharm Therapeutics E10 Chart

Karyopharm Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -4.07 -3.12 -3.09

Karyopharm Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.12 -3.13 -3.10 -3.12 -3.09

Competitive Comparison of Karyopharm Therapeutics's E10

For the Biotechnology subindustry, Karyopharm Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karyopharm Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Karyopharm Therapeutics's Shiller PE Ratio falls into.



Karyopharm Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Karyopharm Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.36/129.4194*129.4194
=-0.360

Current CPI (Dec. 2023) = 129.4194.

Karyopharm Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201403 -0.460 99.695 -0.597
201406 -0.550 100.560 -0.708
201409 -0.610 100.428 -0.786
201412 -0.790 99.070 -1.032
201503 -0.740 99.621 -0.961
201506 -0.920 100.684 -1.183
201509 -0.850 100.392 -1.096
201512 -0.810 99.792 -1.050
201603 -0.750 100.470 -0.966
201606 -0.840 101.688 -1.069
201609 -0.690 101.861 -0.877
201612 -0.650 101.863 -0.826
201703 -0.710 102.862 -0.893
201706 -0.640 103.349 -0.801
201709 -0.650 104.136 -0.808
201712 -0.800 104.011 -0.995
201803 -0.780 105.290 -0.959
201806 -0.600 106.317 -0.730
201809 -0.790 106.507 -0.960
201812 -0.960 105.998 -1.172
201903 -1.090 107.251 -1.315
201906 -0.710 108.070 -0.850
201909 -0.670 108.329 -0.800
201912 -0.760 108.420 -0.907
202003 -0.780 108.902 -0.927
202006 -0.630 108.767 -0.750
202009 -0.730 109.815 -0.860
202012 -0.590 109.897 -0.695
202103 -0.770 111.754 -0.892
202106 -0.710 114.631 -0.802
202109 -0.690 115.734 -0.772
202112 0.460 117.630 0.506
202203 -0.530 121.301 -0.565
202206 -0.620 125.017 -0.642
202209 -0.450 125.227 -0.465
202212 -0.430 125.222 -0.444
202303 -0.300 127.348 -0.305
202306 -0.290 128.729 -0.292
202309 -0.300 129.860 -0.299
202312 -0.360 129.419 -0.360

Add all the adjusted EPS together and divide 10 will get our e10.


Karyopharm Therapeutics  (NAS:KPTI) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Karyopharm Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Karyopharm Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Karyopharm Therapeutics (Karyopharm Therapeutics) Business Description

Traded in Other Exchanges
Address
85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Executives
Richard A. Paulson director, officer: President and CEO 85 WELLS AVENUE, NEWTON MA 02459
Garen G Bohlin director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Michael Mason officer: EVP, CFO, Treasurer 300 3RD STREET, CAMBRIDGE MA 02142
Michael Mano officer: SVP, General Counsel&Secretary 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Sohanya Roshan Cheng officer: SVP Sales & Commercial Ops C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON MA 02459
Zhen Su director 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Stuart Poulton officer: EVP, Chief Development Officer 85 WELLS AVENUE, NEWTON MA 02459
Reshma Rangwala officer: EVP & Chief Medical Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Stephen Mitchener officer: SVP, Chief Business Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Ran Frenkel officer: EVP, WW Development Operations C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, 2ND FLOOR, NEWTON MA 02459
Jatin Shah officer: EVP, Chief Medical Officer C/O KARYOPHARM THERAPEUTICS, INC., 85 WELLS AVENUE, NEWTON MA 02459
Sharon Shacham officer: C.S.O & Pres. of Res & Develop C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Michael Kauffman director, officer: President, C.E.O., C.M.O. C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Peter Honig director 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037

Karyopharm Therapeutics (Karyopharm Therapeutics) Headlines